11. January 2018
Researchers have developed a capsule that can deliver a week’s worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule of dosing required for the drug cocktails used to fight the virus, the researchers say.
21. March 2016
Purpose The effectiveness of Tenofovir based HIV pre-exposure prophylaxis (PrEP) is proven, but hinges on correct and consistent use. User compliance and therapeutic effectiveness can be improved by long acting drug delivery systems. Here we describe a thin-film polymer device (TFPD) as a biodegradable subcutaneous implant for PrEP. Methods A thin-film polycaprolactone (PCL) membrane controls drug release from a reservoir. To achieve membrane controlled release, TAF requires a formulation...
24. December 2015
Pre-exposure prophylaxis (PrEP) is one of the best preventive strategies in protection against HIV/AIDS. The present research approach is development of novel topical thermosensitive mucoadhesive in situ gel for intravaginal use. Tenofovir disoproxil fumarate (TDF) has been loaded in the formulation and cold method was followed to prepare the various formulations. More
10. June 2015
Washington, D.C.—June 8, 2015— The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the announcement of tentative approval by the U.S. Food and Drug Administration of a new antiretroviral treatment (ART) formulation that will make it easier for children living with HIV to ingest their medication. The oral pellets, manufactured by Indian generic medicines manufacturer CIPLA, contain an antiretroviral formulation of lopinavir and ritonavir (LPV/r) that can be mixed into a child’s...